19 June 2013
Keywords: supergen, update, nipent, firm, said, due, lower-than-
Article | 05 January 2004
US firm SuperGen has said that, due to lower-than- expected demand forNipent (pentostatin for injection) during the fourth quarter, total
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 January 2004
22 December 2003
18 June 2013
© 2013 thepharmaletter.com